Correction: Integrative analysis identifies an older female-linked AML patient group with better risk in ECOG-ACRIN Cancer Research Group's clinical trial E3999
Blood Cancer J
.
2023 Jul 6;13(1):103.
doi: 10.1038/s41408-023-00862-2.
Authors
Franck Rapaport
#
1
2
,
Kenneth Seier
#
3
,
Yaseswini Neelamraju
#
4
,
Duane Hassane
5
,
Timour Baslan
6
,
Daniel T Gildea
4
,
Samuel Haddox
4
,
Tak Lee
5
,
H Moses Murdock
7
,
Caroline Sheridan
5
,
Alexis Thurmond
4
,
Ling Wang
5
,
Martin Carroll
7
,
Larry D Cripe
8
,
Hugo Fernandez
9
,
Christopher E Mason
10
11
12
,
Elisabeth Paietta
13
,
Gail J Roboz
14
,
Zhuoxin Sun
15
,
Martin S Tallman
16
,
Yanming Zhang
17
,
Mithat Gönen
#
3
,
Ross Levine
#
1
,
Ari M Melnick
#
5
,
Maria Kleppe
1
,
Francine E Garrett-Bakelman
18
19
20
21
Affiliations
1
Human Oncology and Pathogenesis Program, Molecular Cancer Medicine Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
2
Center for Clinical and Translational Science, The Rockefeller University, New York, NY, USA.
3
Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
4
Department of Biochemistry and Molecular Genetics, University of Virginia, Charlottesville, VA, USA.
5
Division of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medicine, New York, NY, USA.
6
Cancer Biology and Genetics Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
7
Division of Hematology and Oncology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.
8
Simon Cancer Center, Indiana University, Indianapolis, IN, USA.
9
Department of Malignant Hematology & Cellular Therapy, Moffitt Cancer Center, Tampa, FL, USA.
10
Department of Physiology and Biophysics, Weill Cornell Medicine, New York, NY, USA.
11
Institute for Computational Biomedicine, Weill Cornell Medicine, New York, NY, USA.
12
The WorldQuant Initiative for Quantitative Prediction, Weill Cornell Medicine, New York, USA.
13
Montefiore Medical Center, Bronx, NY, USA.
14
Weill Cornell Medicine and The New York Presbyterian Hospital, New York, NY, USA.
15
Dana-Farber Cancer Institute, Boston, MA, USA.
16
Memorial Sloan Kettering Cancer Center, New York, NY, USA.
17
Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
18
Department of Biochemistry and Molecular Genetics, University of Virginia, Charlottesville, VA, USA. fg5q@virginia.edu.
19
Division of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medicine, New York, NY, USA. fg5q@virginia.edu.
20
Department of Medicine, University of Virginia, Charlottesville, VA, USA. fg5q@virginia.edu.
21
University of Virginia Cancer Center, Charlottesville, VA, USA. fg5q@virginia.edu.
#
Contributed equally.
PMID:
37407550
PMCID:
PMC10322919
DOI:
10.1038/s41408-023-00862-2
No abstract available
Publication types
Published Erratum
Grants and funding
P30 CA044579/CA/NCI NIH HHS/United States